Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

The global drug device combination products market, valued at US$224.70 billion in 2024, stood at US$243.02 billion in 2025 ...

Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects.

Kenya is among the low- and middle-income countries (LMICs) whose children and young people (CYP) face gross inequities when it comes to the diagnosis and treatment of type 1 diabetes (T1D). These are ...

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

This move is a milestone, he noted, as for the first time insulin is being produced as pens inside Egypt ... Approximately 15 percent of Egyptians suffer from diabetes, which makes the provision of ...

She stated that the corporate control by Eli Lilly, Novo Nordisk ... Novo Nordisk decided to cease insulin pen production to prioritize its GLP-1 medications for diabetes and obesity, like ...

80% of people with diabetes live in low- and middle-income countries, where access to insulin pens is extremely limited due primarily to high prices Eli Lilly, Novo Nordisk, and Sanofi control and ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi ... Panama and the U.S., found 82% of people with diabetes prefer pens over insulin in vials injected with syringes.